Mechanism of action
Red blood cell transfusion is a form of replacement therapy that directly increases the oxygen-carrying capacity of blood by providing functional hemoglobin. Each unit of packed RBCs contains approximately 200-250 mL of erythrocytes suspended in a small volume of plasma and preservative solution.
The mechanism is straightforward: transfused RBCs circulate and bind oxygen in the lungs, then release it to hypoxic tissues. One unit typically raises hemoglobin by approximately 1 g/dL and hematocrit by 3% in an average adult without active bleeding.
RBC products do not correct coagulopathy, thrombocytopenia, or provide clotting factors—they address only the oxygen-carrying deficit. The lifespan of transfused RBCs varies but is generally shorter than native cells, averaging 60-90 days depending on storage time before transfusion.
- Restrictive transfusion threshold (Hb <7 g/dL) is standard for stable patients; exceptions include acute coronary syndrome (consider 8 g/dL)
- Acute hemolytic transfusion reaction from ABO incompatibility causes fever, flank pain, hypotension, dark urine, and DIC—stop transfusion immediately
- One unit of packed RBCs raises hemoglobin by approximately 1 g/dL and hematocrit by 3% in adults without active bleeding
- TRALI presents with acute hypoxemia and bilateral pulmonary infiltrates within 6 hours of transfusion; it is non-cardiogenic pulmonary edema
- O-negative blood is the universal RBC donor; O-positive can be used for males and post-menopausal females in emergencies
- Never infuse calcium-containing solutions or D5W with RBCs—calcium causes clotting, hypotonic solutions cause hemolysis
- Chronic transfusion (>10-20 units) causes iron overload requiring chelation therapy with deferoxamine or deferasirox
- Leukoreduction decreases febrile non-hemolytic reactions and CMV transmission; irradiation prevents TA-GVHD in immunocompromised patients
Indications
Acute hemorrhage
RBC transfusion is indicated for acute blood loss with hemodynamic instability or signs of inadequate tissue perfusion despite fluid resuscitation. The decision is based on clinical assessment rather than hemoglobin values alone in actively bleeding patients.
Symptomatic anemia
Transfusion is appropriate for patients with symptoms attributable to anemia including:
- Tachycardia, dyspnea, or angina
- Altered mental status
- Lactic acidosis from tissue hypoxia
Hemoglobin thresholds
The restrictive strategy (transfuse at Hb <7 g/dL) is recommended for most hospitalized stable patients and has shown equivalent or superior outcomes compared to liberal strategies. Exceptions include:
- Acute coronary syndrome: consider threshold of 8 g/dL
- Severe thrombocytopenia with bleeding: individualized approach
- Chronic transfusion-dependent anemia: maintain Hb based on underlying condition (e.g., thalassemia, sickle cell disease)
Perioperative setting
RBC transfusion may be needed for surgical blood loss, particularly in cardiac, vascular, and orthopedic procedures. Preoperative anemia optimization reduces transfusion needs.
Chronic anemia
Transfusion is reserved for failure of other therapies (iron, erythropoietin-stimulating agents) and significant symptoms. Chronic transfusion carries iron overload risk.
Pharmacokinetics
Red blood cells are administered intravenously through large-bore catheters (18-gauge or larger preferred) to avoid hemolysis. Each unit is typically infused over 2-4 hours; rapid transfusion (over 30-60 minutes) may be necessary in massive hemorrhage.
Distribution: RBCs remain in the intravascular space and do not distribute to extravascular compartments. The increase in hemoglobin is dose-dependent and predictable in non-bleeding patients.
Metabolism and elimination: Senescent transfused RBCs are removed by the reticuloendothelial system, primarily in the spleen and liver. Hemoglobin is broken down to bilirubin, which is conjugated and excreted. Iron is recycled for erythropoiesis.
Storage and compatibility: RBCs are stored at 1-6°C and have a shelf life of 35-42 days depending on anticoagulant-preservative solution. ABO and Rh typing with antibody screening (type and screen) or full crossmatching (type and cross) is required. In life-threatening emergencies, O-negative (universal donor) or type-specific uncrossmatched blood may be used.
Adverse effects
Acute transfusion reactions
Acute hemolytic transfusion reaction (AHTR): Results from ABO incompatibility, causing intravascular hemolysis with fever, chills, flank pain, hypotension, dark urine, and disseminated intravascular coagulation (DIC). This is a medical emergency with mortality risk. Stop transfusion immediately.
Febrile non-hemolytic transfusion reaction (FNHTR): Temperature rise ≥1°C with chills during or shortly after transfusion, caused by cytokines from donor leukocytes. Common (1-2% of transfusions). Leukoreduction reduces incidence.
Allergic reactions: Range from mild urticaria (most common) to anaphylaxis. Caused by recipient antibodies against donor plasma proteins. Antihistamines treat mild reactions; severe reactions require epinephrine.
Transfusion-related acute lung injury (TRALI): Non-cardiogenic pulmonary edema within 6 hours of transfusion, presenting with acute hypoxemia, bilateral infiltrates, and dyspnea. Caused by donor antibodies activating recipient neutrophils. Supportive care; usually resolves in 48-96 hours.
Transfusion-associated circulatory overload (TACO): Volume overload causing cardiogenic pulmonary edema, especially in elderly or those with cardiac/renal dysfunction. Presents with hypertension, jugular venous distension, and pulmonary edema. Treat with diuretics and slow transfusion rate.
Delayed complications
Delayed hemolytic transfusion reaction: Occurs 3-14 days post-transfusion due to anamnestic antibody response. Presents with mild hemolysis, jaundice, and falling hemoglobin.
Iron overload: Chronic transfusion (>10-20 units lifetime) causes hemosiderosis affecting heart, liver, and endocrine organs. Requires iron chelation therapy.
Transfusion-transmitted infections: Rare with modern screening but include HIV, hepatitis B/C, and emerging pathogens. Risk is extremely low (<1:1,000,000 for HIV/HCV in developed countries).
Immunosuppression: Transfusion-related immunomodulation may increase infection and cancer recurrence risk, though clinical significance is debated.
Alloimmunization: Development of antibodies against RBC antigens, complicating future transfusions and pregnancy. More common in chronically transfused patients.
Contraindications and warnings
Absolute contraindications
- Transfusion without proper ABO/Rh compatibility testing (except life-threatening emergency with O-negative blood)
- Patient refusal (competent adult)
Relative contraindications and cautions
Volume overload risk: Use caution in heart failure, renal insufficiency, and elderly patients. Consider slower infusion rates, diuretics, or smaller aliquots.
Warm autoimmune hemolytic anemia: Transfusion may exacerbate hemolysis but is necessary if life-threatening anemia exists. Use least incompatible units.
IgA deficiency: Patients with anti-IgA antibodies risk anaphylaxis. Use washed RBCs or IgA-deficient donor products.
Special populations
Pregnancy: RhD-negative women of childbearing potential should receive RhD-negative RBCs to prevent alloimmunization and hemolytic disease of the newborn. RBC transfusion in pregnancy follows standard hemoglobin thresholds.
Neonates: Require special small-volume aliquots, irradiated products (to prevent graft-versus-host disease), and CMV-negative or leukoreduced products.
Sickle cell disease: Exchange transfusion or simple transfusion with phenotypically matched RBCs reduces alloimmunization. Goal is to reduce HbS percentage.
Drug interactions
Red blood cell transfusions have limited traditional drug interactions but important compatibility considerations:
Calcium-containing solutions: Do not infuse calcium chloride or calcium gluconate through the same line as RBCs. Calcium can bind citrate anticoagulant in the blood product, causing clotting in the IV tubing.
Hypotonic solutions: Do not administer dextrose 5% in water (D5W) or other hypotonic solutions with RBCs—causes hemolysis. Use normal saline (0.9% NaCl) for priming lines and concurrent infusion if needed.
Medications in IV lines: Do not add medications to RBC units. Flush lines with saline before and after transfusion if medications must be given through the same access.
Warfarin and anticoagulants: No direct interaction, but transfusion may be necessary to manage bleeding complications from anticoagulation. RBCs do not reverse anticoagulant effects.
Erythropoietin-stimulating agents (ESAs): Transfusion may temporarily suppress endogenous erythropoietin and reduce ESA effectiveness. Generally used as alternatives rather than together.
Iron chelators: Chronic transfusion necessitates chelation therapy (deferoxamine, deferasirox) to prevent iron overload. These are complementary rather than interactive.
Clinical pearls
- Restrictive transfusion (Hb <7 g/dL) is preferred for most stable hospitalized adults and reduces mortality, infection, and resource use compared to liberal strategies.
- Type O-negative blood is the universal donor for RBCs and should be used in emergency situations before crossmatching is complete. O-positive can be used for males and post-menopausal females to conserve O-negative supply.
- One unit raises Hb by ~1 g/dL and hematocrit by ~3% in an average adult without ongoing bleeding. Always reassess after single-unit transfusion rather than ordering multiple units upfront.
- Monitor for transfusion reactions in the first 15 minutes: Most acute reactions occur early. Stay at bedside and check vital signs at 5 and 15 minutes after starting transfusion.
- Stop the transfusion immediately if any reaction is suspected. Maintain IV access with saline, check clerical error, send blood bank notification, and obtain post-transfusion labs (CBC, Coombs, haptoglobin, bilirubin, urine hemoglobin).
- Leukoreduction reduces FNHTR and CMV transmission: Most blood banks now provide prestorage leukoreduced RBCs as standard.
- Massive transfusion protocol: In hemorrhagic shock requiring massive transfusion (>10 units in 24 hours), give RBCs, plasma, and platelets in balanced ratios (1:1:1) to prevent dilutional coagulopathy and hypothermia.
- Irradiated RBCs prevent transfusion-associated graft-versus-host disease (TA-GVHD) in immunocompromised patients, neonates, and when donor and recipient share HLA haplotypes (directed donation from relatives).
- Transfusion is not a treatment for asymptomatic chronic anemia: Address the underlying cause (iron deficiency, B12 deficiency, chronic disease, renal failure) rather than reflexively transfusing.
Practice questions
1. A 68-year-old man undergoes elective total hip replacement. On postoperative day 1, his hemoglobin is 7.8 g/dL (preoperative 13.2 g/dL). He is asymptomatic, ambulating with physical therapy, and vital signs are stable. He has a history of well-controlled hypertension. What is the most appropriate management?
2. A 42-year-old woman receives a red blood cell transfusion for symptomatic anemia. Ten minutes after starting the transfusion, she develops fever to 39.2°C, chills, flank pain, and hypotension. Urine appears dark red. What is the most likely diagnosis?
3. A 55-year-old man with chronic transfusion-dependent anemia due to myelodysplastic syndrome has received approximately 40 units of packed RBCs over 3 years. He now presents with fatigue, diabetes mellitus, and elevated liver enzymes. Echocardiogram shows reduced ejection fraction. Serum ferritin is 4,200 ng/mL. What is the most appropriate additional therapy?
Frequently asked questions
How does red blood cell transfusion work?
Red blood cell transfusion works by directly increasing the oxygen-carrying capacity of blood through the delivery of functional hemoglobin. Transfused RBCs circulate in the bloodstream, bind oxygen in the lungs, and transport it to hypoxic tissues. One unit of packed RBCs typically raises hemoglobin by approximately 1 g/dL in an average adult without active bleeding, immediately improving tissue oxygenation.
What are the side effects of red blood cell transfusion?
Red blood cell transfusion can cause acute hemolytic reactions (from ABO incompatibility), febrile non-hemolytic reactions (fever and chills), allergic reactions (urticaria to anaphylaxis), TRALI (acute lung injury), and TACO (volume overload). Delayed complications include delayed hemolytic reactions, iron overload with chronic transfusion, rare transfusion-transmitted infections, and alloimmunization. Most acute reactions occur within the first 15 minutes, requiring close monitoring at the start of transfusion.
When is red blood cell transfusion indicated?
Red blood cell transfusion is indicated for acute hemorrhage with hemodynamic instability, symptomatic anemia causing tachycardia, dyspnea, or altered mental status, and when hemoglobin falls below specific thresholds. The restrictive threshold of hemoglobin <7 g/dL is used for most stable hospitalized patients, while a threshold of 8 g/dL may be considered in acute coronary syndrome. The decision should be based on clinical assessment, not hemoglobin values alone.
What is the difference between packed red blood cells and whole blood?
Packed red blood cells (PRBCs) are whole blood with most plasma removed, resulting in a concentrated RBC product with higher hematocrit (55-65%) and smaller volume (250-350 mL per unit). Whole blood contains RBCs, plasma, clotting factors, and some platelets in physiologic ratios. PRBCs are used for most transfusions to increase oxygen-carrying capacity, while whole blood is being reconsidered for massive hemorrhage and trauma resuscitation where balanced blood component replacement is needed.
Can you be allergic to red blood cell transfusion?
Yes, allergic reactions to RBC transfusion occur, ranging from mild urticaria and itching to life-threatening anaphylaxis. These reactions are typically caused by recipient antibodies reacting against donor plasma proteins remaining in the blood product. Mild reactions are treated with antihistamines, while severe anaphylactic reactions require epinephrine and stopping the transfusion immediately. Patients with IgA deficiency and anti-IgA antibodies are at particularly high risk and may require washed RBCs or IgA-deficient products.
Conditions it is used for
Related drugs
Sources and further reading
DailyMed (FDA labels)StatPearls (NCBI Bookshelf)MedlinePlusWHO ATC/DDD index: B05AX01
Educational content for medical students, prepared by the WhiteCoat Pro editorial team with AI assistance; every page is reviewed by a second AI model for factual errors. It is not medical advice and does not replace the product label, local guidelines or a clinician.